Literature DB >> 16574549

The Calman-Hine report: a personal retrospective on the UK's first comprehensive policy on cancer services.

Robert A Haward1.   

Abstract

Calman-Hine was the first comprehensive cancer report to be produced in the UK, and set out principles for cancer care and the clinical organisation for service delivery. It advocated a change from a generalist model (eg, care given by general surgeons and physicians) that was supported by specialists to a fully specialist service. The process of policy development was innovative and the report was accepted widely throughout the UK. However, implementation, which began at a time of organisational change across the UK National Health Service (NHS), was not addressed sufficiently in the years immediately after publication. Consequently, change was more variable both geographically and within a single location and took longer than necessary. Evidence from research, routine data, and external assessments suggest that the policy was eventually successful and a worthwhile change. Well thought out and sustained mechanisms for policy implementation are as crucial as well-designed policies, and government health reforms can conflict with specific policies for quality improvement.

Entities:  

Mesh:

Year:  2006        PMID: 16574549     DOI: 10.1016/S1470-2045(06)70659-3

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  16 in total

1.  Socioeconomic inequalities in cancer survival in England after the NHS cancer plan.

Authors:  B Rachet; L Ellis; C Maringe; T Chu; U Nur; M Quaresma; A Shah; S Walters; L Woods; D Forman; M P Coleman
Journal:  Br J Cancer       Date:  2010-06-29       Impact factor: 7.640

Review 2.  [Tumor boards: why they are necessary and which structure is needed].

Authors:  B S Halpern; M E Mayerhoefer
Journal:  Radiologe       Date:  2013-04       Impact factor: 0.635

3.  Defining the optimal design of the inflammatory bowel disease multidisciplinary team: results from a multicentre qualitative expert-based study.

Authors:  Pritesh Morar; Jamie Read; Sonal Arora; Ailsa Hart; Janindra Warusavitarne; James Green; Nick Sevdalis; Cathryn Edwards; Omar Faiz
Journal:  Frontline Gastroenterol       Date:  2015-03-26

Review 4.  Multidisciplinary management of rectal cancer: the OSTRICH.

Authors:  David W Dietz
Journal:  J Gastrointest Surg       Date:  2013-07-25       Impact factor: 3.452

Review 5.  How I treat acute lymphoblastic leukemia in older adolescents and young adults.

Authors:  Emily Curran; Wendy Stock
Journal:  Blood       Date:  2015-03-24       Impact factor: 22.113

6.  Multidisciplinary cancer conferences for gastrointestinal malignancies result in measureable treatment changes: a prospective study of 149 consecutive patients.

Authors:  Jacqueline Oxenberg; Wesley Papenfuss; Iyare Esemuede; Kristopher Attwood; Marko Simunovic; Boris Kuvshinoff; Valerie Francescutti
Journal:  Ann Surg Oncol       Date:  2014-10-17       Impact factor: 5.344

Review 7.  The role of a multidisciplinary severe chronic obstructive pulmonary disease hyperinflation service in patient selection for lung volume reduction.

Authors:  Joyce Chew; Ravi Mahadeva
Journal:  J Thorac Dis       Date:  2018-10       Impact factor: 2.895

8.  A national survey of consultants, specialists and specialist registrars in restorative dentistry for the assessment and treatment planning of oral cancer patients.

Authors:  K Dewan; R D Kelly; P Bardsley
Journal:  Br Dent J       Date:  2014-06       Impact factor: 1.626

9.  Establishing the aims, format and function for multidisciplinary team-driven care within an inflammatory bowel disease service: a multicentre qualitative specialist-based consensus study.

Authors:  Pritesh S Morar; Nick Sevdalis; Janindra Warusavitarne; Ailsa Hart; James Green; Cathryn Edwards; Omar Faiz
Journal:  Frontline Gastroenterol       Date:  2017-08-10

Review 10.  What is a virtual multidisciplinary team (vMDT)?

Authors:  A J Munro; S Swartzman
Journal:  Br J Cancer       Date:  2013-06-11       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.